INDUSTRY × Lung Neoplasms × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 6 FDA
NCT05461430 2026-04-13

TraveraRTGx

Travera Inc

Completed
72 enrolled
NCT05462717 2026-04-08

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Revolution Medicines, Inc.

Phase 1 Active not recruiting
222 enrolled
NCT03093116 2026-04-03

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 5 FDA